Although suffering from significant imperfections, the TACT trial is a daring step toward a better understanding of how chelation therapy might affect heart disease. It seemed like a crazy notion in ...
Five patients were enrolled, after which the study closed for slow accrual. Median age was 49 years (range, 20–52 years). Four had AML and 1 had MDS. The median serum ferritin level before HSCT was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results